Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.

May
SunMonTueWedThuFriSat
27282930123456789101112131415161718192021222324252627282930311234567
May
SunMonTueWedThuFriSat
27282930123456789101112131415161718192021222324252627282930311234567
Copyright © Ark Medical Solutions Inc. All Rights Reserved.